Literature DB >> 24790066

Is there a need for new agents with novel mechanisms of action in psoriatic arthritis?

Carl Orr1, Douglas James Veale.   

Abstract

Entities:  

Keywords:  DMARDs (biologic); Psoriatic Arthritis; Treatment

Mesh：

Substances：

Year:  2014        PMID： 24790066     DOI： 10.1136/annrheumdis-2013-204934

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  3 in total

Review 1.  An Overview of Bimekizumab for the Treatment of Psoriatic Arthritis: The Evidence so Far.

Authors:  Daniel G Oliveira; Raquel Faria; Tiago Torres
Journal:  Drug Des Devel Ther       Date:  2021-03-09       Impact factor: 4.162

2.  JAK1 selective inhibitors for the treatment of spondyloarthropathies.

Authors:  Jonathan P E White; Laura C Coates
Journal:  Rheumatology (Oxford)       Date:  2021-05-05       Impact factor: 7.580

Review 3.  The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.

Authors:  Douglas J Veale; Dennis McGonagle; Iain B McInnes; James G Krueger; Christopher T Ritchlin; Dirk Elewaut; Keith S Kanik; Thijs Hendrikx; Gabriel Berstein; Jennifer Hodge; Jean-Baptiste Telliez
Journal:  Rheumatology (Oxford)       Date:  2019-02-01       Impact factor: 7.580
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.